SCHEDULE: Venrock Funds Disclose 9.99% Stake in Zura Bio
Beneficial Ownership Disclosure
Venrock Healthcare Capital Partners and affiliated entities reported a 9.99% beneficial ownership stake in Zura Bio Limited's Class A Ordinary Shares as of June 30, 2025.
Summary
- Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah, and Bong Y. Koh collectively reported beneficial ownership of 6,353,353 Class A Ordinary Shares of Zura Bio Limited.
- This aggregate ownership represents 9.99% of the Class A Ordinary Shares outstanding, rounded down to 9.9% on the cover page due to EDGAR filing system limitations.
- The ownership includes 933,616 Class A Ordinary Shares and pre-funded warrants for up to 1,980,406 shares held by VHCP III.
- VHCP Co-Investment III holds 93,448 Class A Ordinary Shares and pre-funded warrants for up to 198,157 shares.
- VHCP EG holds 3,604,152 Class A Ordinary Shares and pre-funded warrants for up to 7,342,679 shares.
- A 'Beneficial Ownership Blocker' provision in the pre-funded warrants prevents the exercise of warrants if it would result in beneficial ownership exceeding 9.99% of the outstanding Class A Ordinary Shares.
- The beneficial ownership percentage is calculated based on 61,874,998 Class A Ordinary Shares outstanding as of May 5, 2025, plus 1,722,137 Class A Ordinary Shares issuable upon exercise of the pre-funded warrants.
Sentiment
Score: 5
Explanation: This is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the company's performance or prospects.
Future Outlook
NA
Industry Context
This filing is a standard disclosure of significant ownership by institutional investors in a publicly traded company, common in the biotechnology and healthcare sectors where venture capital and private equity funds often hold substantial stakes post-IPO or SPAC merger.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership and potential influence, though the 'Beneficial Ownership Blocker' limits immediate control accumulation.
Key Dates
| Date | Description |
|---|---|
| 2025-05-05 | Date of outstanding Class A Ordinary Shares reported in Issuer's Form 10-Q. |
| 2025-06-30 | Date of event which requires filing of this statement (beneficial ownership snapshot). |
| 2025-08-14 | Date of filing of this Schedule 13G Amendment No. 3. |
Keywords
Zura Bio Limited, Venrock Healthcare Capital Partners, Beneficial Ownership, Schedule 13G, Class A Ordinary Shares, SEC Filing, Investment Funds, Pre-Funded Warrants
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.